Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

NCT01454102 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

472

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Bevacizumab
DRUG: Erlotinib
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb